![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:EZR-INSR (FusionGDB2 ID:HG7430TG3643) |
Fusion Gene Summary for EZR-INSR |
![]() |
Fusion gene information | Fusion gene name: EZR-INSR | Fusion gene ID: hg7430tg3643 | Hgene | Tgene | Gene symbol | EZR | INSR | Gene ID | 7430 | 3643 |
Gene name | ezrin | insulin receptor | |
Synonyms | CVIL|CVL|HEL-S-105|VIL2 | CD220|HHF5 | |
Cytomap | ('EZR')('INSR') 6q25.3 | 19p13.2 | |
Type of gene | protein-coding | protein-coding | |
Description | ezrincytovillin 2epididymis secretory protein Li 105p81villin 2 (ezrin) | insulin receptorIR | |
Modification date | 20200322 | 20200313 | |
UniProtAcc | P15311 | P06213 | |
Ensembl transtripts involved in fusion gene | ENST00000337147, ENST00000367075, ENST00000392177, ENST00000476189, | ||
Fusion gene scores | * DoF score | 26 X 22 X 10=5720 | 20 X 13 X 8=2080 |
# samples | 32 | 20 | |
** MAII score | log2(32/5720*10)=-4.15987133677839 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(20/2080*10)=-3.37851162325373 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: EZR [Title/Abstract] AND INSR [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | EZR(159229021)-INSR(7119557), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | EZR | GO:0048015 | phosphatidylinositol-mediated signaling | 25591774 |
Hgene | EZR | GO:0051017 | actin filament bundle assembly | 10793131 |
Tgene | INSR | GO:0001934 | positive regulation of protein phosphorylation | 7556070 |
Tgene | INSR | GO:0002092 | positive regulation of receptor internalization | 25401701 |
Tgene | INSR | GO:0007186 | G protein-coupled receptor signaling pathway | 9092559 |
Tgene | INSR | GO:0008284 | positive regulation of cell proliferation | 17925406 |
Tgene | INSR | GO:0008286 | insulin receptor signaling pathway | 6849137|8440175|20455999 |
Tgene | INSR | GO:0018108 | peptidyl-tyrosine phosphorylation | 8496180 |
Tgene | INSR | GO:0032148 | activation of protein kinase B activity | 7556070 |
Tgene | INSR | GO:0032869 | cellular response to insulin stimulus | 8440175 |
Tgene | INSR | GO:0043410 | positive regulation of MAPK cascade | 20455999 |
Tgene | INSR | GO:0045725 | positive regulation of glycogen biosynthetic process | 17925406 |
Tgene | INSR | GO:0046326 | positive regulation of glucose import | 3518947 |
Tgene | INSR | GO:0046777 | protein autophosphorylation | 6849137|8496180 |
Tgene | INSR | GO:0060267 | positive regulation of respiratory burst | 9092559 |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for EZR-INSR |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for EZR-INSR |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for EZR-INSR |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:159229021/:7119557) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
EZR | INSR |
FUNCTION: Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis. {ECO:0000269|PubMed:17881735, ECO:0000269|PubMed:18270268, ECO:0000269|PubMed:19111582}. | FUNCTION: Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity). {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for EZR-INSR |
![]() |
Top |
Fusion Gene PPI Analysis for EZR-INSR |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for EZR-INSR |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | INSR | P06213 | DB00046 | Insulin lispro | Agonist | Biotech | Approved |
Tgene | INSR | P06213 | DB00047 | Insulin glargine | Agonist | Biotech | Approved |
Tgene | INSR | P06213 | DB00071 | Insulin pork | Binder | Biotech | Approved |
Tgene | INSR | P06213 | DB01306 | Insulin aspart | Agonist | Biotech | Approved |
Tgene | INSR | P06213 | DB01307 | Insulin detemir | Agonist | Biotech | Approved |
Tgene | INSR | P06213 | DB01309 | Insulin glulisine | Agonist | Biotech | Approved |
Tgene | INSR | P06213 | DB09129 | Chromic chloride | Activator | Small molecule | Approved |
Tgene | INSR | P06213 | DB09564 | Insulin degludec | Ligand | Biotech | Approved |
Tgene | INSR | P06213 | DB14751 | Mecasermin rinfabate | Biotech | Approved | |
Tgene | INSR | P06213 | DB00030 | Insulin human | Agonist | Biotech | Approved|Investigational |
Tgene | INSR | P06213 | DB01277 | Mecasermin | Biotech | Approved|Investigational | |
Tgene | INSR | P06213 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | INSR | P06213 | DB12267 | Brigatinib | Binding | Small molecule | Approved|Investigational |
Top |
Related Diseases for EZR-INSR |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | EZR | C0033578 | Prostatic Neoplasms | 3 | CTD_human |
Hgene | EZR | C0376358 | Malignant neoplasm of prostate | 3 | CTD_human |
Hgene | EZR | C0007097 | Carcinoma | 1 | CTD_human |
Hgene | EZR | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Hgene | EZR | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
Hgene | EZR | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
Hgene | EZR | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
Hgene | EZR | C0029408 | Degenerative polyarthritis | 1 | CTD_human |
Hgene | EZR | C0086743 | Osteoarthrosis Deformans | 1 | CTD_human |
Hgene | EZR | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
Hgene | EZR | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
Hgene | EZR | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
Hgene | EZR | C0205699 | Carcinomatosis | 1 | CTD_human |
Hgene | EZR | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human |
Tgene | C0265344 | Donohue Syndrome | 23 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0342278 | Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans | 18 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0271695 | Rabson-Mendenhall Syndrome | 10 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 3 | UNIPROT | |
Tgene | C0002152 | Alloxan Diabetes | 2 | CTD_human | |
Tgene | C0011853 | Diabetes Mellitus, Experimental | 2 | CTD_human | |
Tgene | C0020459 | Hyperinsulinism | 2 | CTD_human | |
Tgene | C0021655 | Insulin Resistance | 2 | CTD_human | |
Tgene | C0024115 | Lung diseases | 2 | CTD_human | |
Tgene | C0038433 | Streptozotocin Diabetes | 2 | CTD_human | |
Tgene | C0342336 | Insulin resistance - type A | 2 | ORPHANET | |
Tgene | C0920563 | Insulin Sensitivity | 2 | CTD_human | |
Tgene | C1257963 | Endogenous Hyperinsulinism | 2 | CTD_human | |
Tgene | C1257964 | Exogenous Hyperinsulinism | 2 | CTD_human | |
Tgene | C1257965 | Compensatory Hyperinsulinemia | 2 | CTD_human | |
Tgene | C1864952 | Hyperinsulinemic Hypoglycemia, Familial, 5 | 2 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0002395 | Alzheimer's Disease | 1 | CTD_human | |
Tgene | C0011265 | Presenile dementia | 1 | CTD_human | |
Tgene | C0011882 | Diabetic Neuropathies | 1 | CTD_human | |
Tgene | C0013146 | Drug abuse | 1 | CTD_human | |
Tgene | C0013170 | Drug habituation | 1 | CTD_human | |
Tgene | C0013222 | Drug Use Disorders | 1 | CTD_human | |
Tgene | C0020429 | Hyperalgesia | 1 | CTD_human | |
Tgene | C0020456 | Hyperglycemia | 1 | CTD_human | |
Tgene | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human | |
Tgene | C0030567 | Parkinson Disease | 1 | CTD_human | |
Tgene | C0038580 | Substance Dependence | 1 | CTD_human | |
Tgene | C0038586 | Substance Use Disorders | 1 | CTD_human | |
Tgene | C0235833 | Congenital diaphragmatic hernia | 1 | CTD_human | |
Tgene | C0236969 | Substance-Related Disorders | 1 | CTD_human | |
Tgene | C0265699 | Congenital hernia of foramen of Morgagni | 1 | CTD_human | |
Tgene | C0265700 | Congenital hernia of foramen of Bochdalek | 1 | CTD_human | |
Tgene | C0271650 | Impaired glucose tolerance | 1 | CTD_human | |
Tgene | C0271673 | Symmetric Diabetic Proximal Motor Neuropathy | 1 | CTD_human | |
Tgene | C0271674 | Asymmetric Diabetic Proximal Motor Neuropathy | 1 | CTD_human | |
Tgene | C0271678 | Diabetic Mononeuropathy | 1 | CTD_human | |
Tgene | C0271680 | Diabetic Polyneuropathies | 1 | CTD_human | |
Tgene | C0271685 | Diabetic Amyotrophy | 1 | CTD_human | |
Tgene | C0271686 | Diabetic Autonomic Neuropathy | 1 | CTD_human | |
Tgene | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human | |
Tgene | C0393835 | Diabetic Asymmetric Polyneuropathy | 1 | CTD_human | |
Tgene | C0458247 | Allodynia | 1 | CTD_human | |
Tgene | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human | |
Tgene | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human | |
Tgene | C0740858 | Substance abuse problem | 1 | CTD_human | |
Tgene | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human | |
Tgene | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human | |
Tgene | C0751074 | Diabetic Neuralgia | 1 | CTD_human | |
Tgene | C0751211 | Hyperalgesia, Primary | 1 | CTD_human | |
Tgene | C0751212 | Hyperalgesia, Secondary | 1 | CTD_human | |
Tgene | C0751213 | Tactile Allodynia | 1 | CTD_human | |
Tgene | C0751214 | Hyperalgesia, Thermal | 1 | CTD_human | |
Tgene | C0752347 | Lewy Body Disease | 1 | CTD_human | |
Tgene | C1510472 | Drug Dependence | 1 | CTD_human | |
Tgene | C1855520 | Hyperglycemia, Postprandial | 1 | CTD_human | |
Tgene | C2936719 | Mechanical Allodynia | 1 | CTD_human | |
Tgene | C4316881 | Prescription Drug Abuse | 1 | CTD_human |